Present work provides a novel rationale to support preclinical and clinical efforts to block VEGFA signaling at multiple levels, using inhibitors of VEGFR, Src and DNA methyltransferases to target ovarian cancer stem‐like cells. This evidence concerns the gene VEGFA and ovarian carcinoma.